Margrethe Bang Henriksen, Ole Hilberg, Christian Juul, Rasmus Thomsen, Sara Witting Christensen Wen, Morten Borg, Andreas Fanø, Alon Lanyado, Itamar Menuhin-Gruman
{"title":"利用ml开发的风险预测算法在高危人群中最大化肺癌筛查:丹麦对LungFlag的回顾性验证。","authors":"Margrethe Bang Henriksen, Ole Hilberg, Christian Juul, Rasmus Thomsen, Sara Witting Christensen Wen, Morten Borg, Andreas Fanø, Alon Lanyado, Itamar Menuhin-Gruman","doi":"10.1016/j.cllc.2025.05.017","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Early detection of lung cancer (LC) is crucial for curative treatment, but current screening methods face challenges due to high costs and poor adherence. Artificial intelligence tools, such as the LungFlag model, uses routine clinical data for innovative risk stratification. This study validates LungFlag in Danish high-risk populations to assess its potential in LC screening.</p><p><strong>Methods: </strong>This retrospective study included data from 2 populations in Southern Denmark (2013-2021): (A) LC fast-track clinic patients (∼25% LC incidence) and (B) outpatients followed with chronic obstructive pulmonary disease (COPD) (∼6% LC incidence). Data included laboratory results, comorbidities, body mass index (BMI), and smoking history from up to 3 years prior to the index date. LungFlag's performance was compared to the PLCOm2012 model. Model interpretation was conducted using Shapley additive explanation (SHAP) values, and risk stratification was analyzed by age.</p><p><strong>Results: </strong>In Population A, 5271 LC cases were identified from 18,600 patients, with a stable LC incidence of 28%. In Population B, LC incidence varied by index-date approach: 6.6% using the diagnosis date and 2.1% using the first visit approach. LungFlag outperformed PLCOm2012 in Population A (AUC: 0.63 vs. 0.60) and showed slightly higher sensitivity in Population B, though differences were minor. Key predictors included smoking, age, and COPD. High-risk individuals identified by LungFlag were generally younger compared to using PLCOm2012.</p><p><strong>Conclusion: </strong>LungFlag demonstrates promise as a decision-support tool in detecting LC, particularly for COPD patients, who lack systematized screening. However, prospective real-world studies are needed to confirm its effectiveness and clinical value.</p>","PeriodicalId":10490,"journal":{"name":"Clinical lung cancer","volume":" ","pages":""},"PeriodicalIF":3.3000,"publicationDate":"2025-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Maximizing Lung Cancer Screening in High-Risk Population Leveraging ML-Developed Risk-Prediction Algorithms: Danish Retrospective Validation of LungFlag.\",\"authors\":\"Margrethe Bang Henriksen, Ole Hilberg, Christian Juul, Rasmus Thomsen, Sara Witting Christensen Wen, Morten Borg, Andreas Fanø, Alon Lanyado, Itamar Menuhin-Gruman\",\"doi\":\"10.1016/j.cllc.2025.05.017\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Early detection of lung cancer (LC) is crucial for curative treatment, but current screening methods face challenges due to high costs and poor adherence. Artificial intelligence tools, such as the LungFlag model, uses routine clinical data for innovative risk stratification. This study validates LungFlag in Danish high-risk populations to assess its potential in LC screening.</p><p><strong>Methods: </strong>This retrospective study included data from 2 populations in Southern Denmark (2013-2021): (A) LC fast-track clinic patients (∼25% LC incidence) and (B) outpatients followed with chronic obstructive pulmonary disease (COPD) (∼6% LC incidence). Data included laboratory results, comorbidities, body mass index (BMI), and smoking history from up to 3 years prior to the index date. LungFlag's performance was compared to the PLCOm2012 model. Model interpretation was conducted using Shapley additive explanation (SHAP) values, and risk stratification was analyzed by age.</p><p><strong>Results: </strong>In Population A, 5271 LC cases were identified from 18,600 patients, with a stable LC incidence of 28%. In Population B, LC incidence varied by index-date approach: 6.6% using the diagnosis date and 2.1% using the first visit approach. LungFlag outperformed PLCOm2012 in Population A (AUC: 0.63 vs. 0.60) and showed slightly higher sensitivity in Population B, though differences were minor. Key predictors included smoking, age, and COPD. High-risk individuals identified by LungFlag were generally younger compared to using PLCOm2012.</p><p><strong>Conclusion: </strong>LungFlag demonstrates promise as a decision-support tool in detecting LC, particularly for COPD patients, who lack systematized screening. However, prospective real-world studies are needed to confirm its effectiveness and clinical value.</p>\",\"PeriodicalId\":10490,\"journal\":{\"name\":\"Clinical lung cancer\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":3.3000,\"publicationDate\":\"2025-06-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical lung cancer\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.cllc.2025.05.017\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical lung cancer","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.cllc.2025.05.017","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
背景:早期发现肺癌(LC)对于根治性治疗至关重要,但目前的筛查方法由于成本高和依从性差而面临挑战。人工智能工具,如LungFlag模型,使用常规临床数据进行创新的风险分层。本研究在丹麦高危人群中验证了LungFlag,以评估其在LC筛查中的潜力。方法:本回顾性研究纳入了丹麦南部2个人群(2013-2021)的数据:(A) LC快速通道临床患者(LC发生率约25%)和(B)慢性阻塞性肺疾病(COPD)门诊患者(LC发生率约6%)。数据包括实验室结果、合并症、身体质量指数(BMI)和指数日期前3年的吸烟史。将LungFlag的性能与PLCOm2012模型进行了比较。采用Shapley加性解释(SHAP)值进行模型解释,并按年龄进行风险分层分析。结果:在人群A中,18,600例患者中发现了5271例LC, LC发病率稳定在28%。在人群B中,LC的发病率因指标日期法而异:诊断日期法为6.6%,首次就诊法为2.1%。LungFlag在种群A中的表现优于PLCOm2012 (AUC: 0.63 vs. 0.60),在种群B中的敏感性略高,但差异不大。主要预测因素包括吸烟、年龄和慢性阻塞性肺病。与使用PLCOm2012相比,lunflag识别的高危人群通常更年轻。结论:LungFlag有望成为检测LC的决策支持工具,特别是对于缺乏系统筛查的COPD患者。然而,需要前瞻性的现实世界研究来证实其有效性和临床价值。
Maximizing Lung Cancer Screening in High-Risk Population Leveraging ML-Developed Risk-Prediction Algorithms: Danish Retrospective Validation of LungFlag.
Background: Early detection of lung cancer (LC) is crucial for curative treatment, but current screening methods face challenges due to high costs and poor adherence. Artificial intelligence tools, such as the LungFlag model, uses routine clinical data for innovative risk stratification. This study validates LungFlag in Danish high-risk populations to assess its potential in LC screening.
Methods: This retrospective study included data from 2 populations in Southern Denmark (2013-2021): (A) LC fast-track clinic patients (∼25% LC incidence) and (B) outpatients followed with chronic obstructive pulmonary disease (COPD) (∼6% LC incidence). Data included laboratory results, comorbidities, body mass index (BMI), and smoking history from up to 3 years prior to the index date. LungFlag's performance was compared to the PLCOm2012 model. Model interpretation was conducted using Shapley additive explanation (SHAP) values, and risk stratification was analyzed by age.
Results: In Population A, 5271 LC cases were identified from 18,600 patients, with a stable LC incidence of 28%. In Population B, LC incidence varied by index-date approach: 6.6% using the diagnosis date and 2.1% using the first visit approach. LungFlag outperformed PLCOm2012 in Population A (AUC: 0.63 vs. 0.60) and showed slightly higher sensitivity in Population B, though differences were minor. Key predictors included smoking, age, and COPD. High-risk individuals identified by LungFlag were generally younger compared to using PLCOm2012.
Conclusion: LungFlag demonstrates promise as a decision-support tool in detecting LC, particularly for COPD patients, who lack systematized screening. However, prospective real-world studies are needed to confirm its effectiveness and clinical value.
期刊介绍:
Clinical Lung Cancer is a peer-reviewed bimonthly journal that publishes original articles describing various aspects of clinical and translational research of lung cancer. Clinical Lung Cancer is devoted to articles on detection, diagnosis, prevention, and treatment of lung cancer. The main emphasis is on recent scientific developments in all areas related to lung cancer. Specific areas of interest include clinical research and mechanistic approaches; drug sensitivity and resistance; gene and antisense therapy; pathology, markers, and prognostic indicators; chemoprevention strategies; multimodality therapy; and integration of various approaches.